Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial

Noureddin M, Khan S, Portell F, Jorkasky D, Dennis J, Khan O, Johansson L, Johansson E, Sanyal A


Lancet Gastroenterol. Hepatol. 2023 Oct 5. doi: 10.1016/S2468-1253(23)00198-X

View abstract Share on Linkedin Share on Twitter